Xiaolong Zhao

Xiaolong Zhao

Auto-generated profile, based on publicly available information

Xiaolong Zhao

Department of Endocrinology, Shanghai Public Health Clinical Center, Shanghai, China

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2007 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
XZXiaolong Zhao
Xiaolong Zhao
KHKaihong Huang
Kaihong Huang
ZZZhaohua Zhu
Zhaohua Zhu
SCShuhong Chen
Shuhong Chen
RHRenming Hu
Renming Hu

1 November 2017 in Medicine
Verified
Journal Article
Open access
MZMei Fang Zeng
Mei Fang Zeng
LCLi Li Chen
Li Li Chen
HYHong Ying Ye
Hong Ying Ye
WGWei Gong
Wei Gong
LZLi Nuo Zhou
Li Nuo Zhou
XZXiao Long Zhao
Xiao Long Zhao
Nivolumab is a monoclonal IgG antibody blocking programmed death receptor-1 (PD1), leading to restoration of the natural T-cell-mediated immune response against the cancer cells. However, it also causes plenty of autoimmune-related adverse events, which often involves endocrine system. A 54-year-old male with renal clear cell carcinoma was treated with nivolumab intravenously. Routine monitoring showed elevated thyroid-stimulating hormone and low free thyroxine after the 6th administration of nivolumab. After the 12th administration, he developed general fatigue, recurrent hypoglycemia, and relative hypotension. Laboratory tests showed low sodium, low morning cortisol without correspondence increase of corticotrophin (ACTH). Other pituitary hormones were normal. MRI showed no space-occupying lesions, but heterogeneous enhancement of the pituitary gland. Primary hypothyroidism and isolated ACTH deficiency. The etiologies were assumed to be nivolumab induced autoimmune lymphocytic thyroiditis and hypophysitis, respectively. Hormone replacements with levothyroxine and acetate cortisone were given orally. Nivolumab was adjusted to lower dose and longer interval. The patient felt good after adequate replacement. Nivolumab was returned to routine dose and interval six months later. And the metastasis was not obviously progressed during this time. The present report provides the first detailed presentation of combined hypothyroidism and isolated ACTH deficiency induced by nivolumab. Adrenal deficiency often develops insidiously. We suggest routine monitoring of fasting blood-glucose, blood pressure and serum sodium as well as thyroid function during nivolumab and other cancer immunotherapies. When unexpected fatigue, hypoglycemia, hypotension or hyponatremia appeared, adrenal deficiency should be taken into consideration.

24 September 2012 in BMC Public Health
Verified
Journal Article
Open access
PDF file
XZXiaolong Zhao
Xiaolong Zhao
XZXiaoming Zhu
Xiaoming Zhu
HZHengsheng Zhang
Hengsheng Zhang
WZWeiwei Zhao
Weiwei Zhao
JLJinhui Li
Jinhui Li
YLYiming Li
Yiming Li
To examine the prevalence of diabetes and prediabetes in Songming county, Yunnan province, South-west China and examine influences of anthropometric indicators on diabetic risk.

11 October 2011 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
XZXiaolong Zhao
Xiaolong Zhao
HMHuangFu Chang Mei
HuangFu Chang Mei
LCLili Chen
Lili Chen
LJLin Jiang
Lin Jiang
MHMin He
Min He
RHRenming Hu
Renming Hu

15 August 2017 in Nutrition & Metabolism
Verified
Journal Article
Open access
PDF file
LCLili Chen
Lili Chen
XZXiaolong Zhao
Xiaolong Zhao
GLGuangjun Liang
Guangjun Liang
JSJiuru Sun
Jiuru Sun
ZLZhifeng Lin
Zhifeng Lin
YLYiming Li
Yiming Li
Secreted frizzled-related protein 5 (SFRP5) is an anti-inflammatory adipokine modulating metabolism dysfunction. This study aims to observe the effect of recombinant SFRP5 protein on nonalcoholic steatohepatitis (NASH). We set up a prokaryotic expression system and purified the recombinant SFRP5 protein. Recombinant SFRP5 protein was further identified by SDS-PAGE, western blot, high performance liquid chromatography (HPLC), protein mass spectrometry and in vitro Wnt5a-binding test. NASH mouse model was induced by methionine and choline deficient diet (MCDD) for 2 weeks. SFRP5 treatment group received intraperitoneal injection with a dosage of 10μg/kg SFRP5 twice a day for 2 weeks. Saline was used as control. Inflammation and fatty lesion score of liver tissue pathology and serum transaminase level were compared. The purity of recombinant SFRP5 protein is 90% identified by HPLC. Its molecule size is 36,096.08 tested by mass spectrometry. Recombinant SFRP5 can specifically bind with Wnt5a which verifies its activity in vitro. The endotoxin level of this recombinant protein is 0.01EU/μg-0.1EU/μg and is suitable for animal experiment. SFRP5 can significantly improve liver inflammation (SFRP5 vs. control, 1.40 ± 0.70 vs. 2.00 ± 0.47, P < 0.05) as well as fatty lesion scores (SFRP5 vs. control, 1.40 ± 0.97 vs. 2.20 ± 0.63, P < 0.05), and lower ALT and AST levels. The mRNA expression of proinflammatory adipokines (IL-1β, IL-6, TNFα and MCP-1) in liver was down-regulated significantly after SFRP5 intervention. Immunohistochemistry and quantitative PCR revealed a dramatically down-regulation of F4/80 in liver after SFRP5 treatment. Recombinant SFRP5 protein significantly alleviated NASH induced by MCDD.

12 March 2021 in Medicine
Verified
Journal Article
Open access
JLJin Li
Jin Li
XZXiaolong Zhao
Xiaolong Zhao
Saroj RaiSaroj Rai
Saroj Rai
YDYuhong Ding
Yuhong Ding
QZQi Zhang
Qi Zhang
PHPan Hong
Pan Hong
A neglected Monteggia fracture is defined as the fracture of the proximal ulna associated with radial head dislocation (RHD) without undergoing any treatment for 4 weeks or more after injury. One-stage operation of ulnar corrective osteotomy and open reduction of RHD might result in many complications. Therefore, a two-stage strategy, including ulnar osteotomy (UO) with or without annular ligament reconstruction (ALR), was adopted at our institute since 2010. We performed a retrospective review of 51 patients with neglected Monteggia fracture between January 2010 and January 2018. Patients with bilateral problems or concomitant injuries in the ipsilateral extremity were excluded. Radiological and clinical data were collected from Hospital Database and clinical visits. All patients were divided into 2 groups based on the status of the ALR: the UO alone (UO) group and the ALR group. There were 15 patients in the UO group and 36 patients in the ALR group. The age in the UO group (6.1 ± 2.3, year) was significantly younger than the ALR group (9.8 ± 2.8, year) (P < .001). Concerning the duration from initial injury to surgery, there was a significant difference between the UO group (8.6 ± 3.2 months) and the ALR group (23.3 ± 12.6 months, P < .001). Concerning the preoperative elbow function, there was no significant difference between the UO group (67.6 ± 5.0) and the ALR group (66.6 ± 4.4) according to the Mayo elbow performance score (MEPS) (P = .51). Concerning the postoperative parameters, including postoperative ROM of the joint, removal of external fixator (6.7 ± 0.8, 6.9 ± 0.9 weeks) (P = .55), lengthening (8.9 ± 2.5, 10.3 ± 2.5 mm) (P = .10) and MEPS (92.7 ± 2.1, 91.6 ± 2.1) (P = .08), there was no significant difference between the UO group and ALR group. Two-stage strategy is a reasonable choice for selected patients with long-lasting RHD with ulnar deformity.